GC Cell and Bifarma Forge Strategic Partnership to Pioneer Cell Therapy Market in Indonesia

20 June 2024 | Thursday | News

MOU between GC Cell and Bifarma to Facilitate the Entry of Immuncell-LC in Indonesia, Expand NK Cell Therapy Pipelines, and Leverage Kalbe Group's Extensive Infrastructure for Accelerated Market Launch

GC Cell, a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma, a frontrunner in stem cell therapy within Indonesia with comprehensive capabilities in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies. Bifarma is a Subsidiary of Southeast Asia's Leading Pharmaceutical, PT Kalbe Farma Tbk.

This strategic partnership marks a significant step towards entering the Indonesian market and expanding into the innovative cell therapy sector, particularly to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for liver cancer surgery in Korea. The MOU also includes discussions on technology transfer and broad cooperation on the development of additional NK cell therapy pipelines.


Furthermore, GC Cell recently unveiled its Blueprint 2.0 strategy, emphasizing a company-wide strategic shift towards future growth drivers. A pivotal component of this strategy is the global market entry of its proprietary cell therapy products, Immuncell-LC, Korea's pioneering cell therapy, along with securing the foundation for NK cell therapy pipelines across the Asia-Pacific region.

Indonesia, known for its large population and robust growth rate coupled with the advent of universal healthcare, presents a promising market for autologous cell therapies. Such therapies are increasingly accessible through medical procedures that are supported by substantial clinical data, similar to those in Japan. Through this strategic partnership with Bifarma and leveraging the Kalbe Group's extensive local infrastructure, including cold chain logistics and a broad hospital network, GC Cell anticipates the accelerated launch of its Immuncell-LC beyond Korea.

James Park, CEO of GC Cell, commented, "This partnership is a testament to the global recognition of our cell therapy expertise, first established in Korea. By combining GC Cell's integrated value chain in cell and gene therapy with Bifarma's strong market presence and capabilities in Indonesia, we are poised to rapidly capture a leading position in the burgeoning field of anti-cancer cell therapies."

"We are pleased to announce that Bifarma, through our cell therapy division ReGeniC, has entered into a MOU with GC Cell, a pioneering biopharmaceutical company from Korea. This strategic collaboration represents a significant milestone for both organizations and reinforces our mission to offer advanced, safe, and high-quality cell therapy," said Dr. Sandy Qlintang, MBiomed., President Director of PT Bifarma Adiluhung.

This MOU represents a significant milestone for both organizations in their pursuit to transform patient care and fortify their positions in the global healthcare landscape.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in